Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 11 May 2022, 14:33 HKT/SGT
Share:
    

Source: Sirnaomics Ltd.
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead(TM) Programs at the TIDES USA 2022

Gaithersburg, MD, USA and Suzhou BioBay, China, May 11, 2022 - (ACN Newswire) - Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and a progress report on its GalAhead(TM) technologies and programs at the TIDES USA 2022 Conference. TIDES 2022 is taking place May 9-12, 2022 at the Hynes Convention Center in Boston.

Oral Presentation Details
-- Presentation Title: mxRNA(TM): Miniaturized RNAi Triggers Composed of Single Oligonucleotides
-- Presentation Segment: Oligonucleotide Discovery, Preclinical and Clinical
-- Presenter: Dmitry Samarsky, PhD, Sirnaomics Chief Technology Officer
-- Time/Date: 9:00am - 9:30am ET, Thursday, May 12, 2022.
-- Location: Hynes Convention Center, Room 102

Dr. Dmitry Samarsky, Sirnaomics Chief Technology Officer, will provide an oral presentation data demonstrating mxRNA efficacy in primary hepatocytes (in vitro) and in mice (in vivo). He will also present results of a 26-week study in non-human primates conducted with the candidate molecule for Sirnaomics' frontrunner GalAhead(TM) therapeutic program, targeting coagulation Factor XI, and report on progress made with other therapeutic programs based on the GalAhead(TM) platform.

For more information about Sirnaomics' presentation, visit the event website here.

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:
Investors:
Nigel Yip
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com

Media (US):
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Media (China):
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com



Topic: Press release summary
Source: Sirnaomics Ltd.

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Sirnaomics Ltd.
July 23, 2024 19:16 HKT/SGT
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
Dec 20, 2022 23:56 HKT/SGT
Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
Dec 14, 2022 23:15 HKT/SGT
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
Dec 14, 2022 11:56 HKT/SGT
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
Nov 8, 2022 08:43 HKT/SGT
Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
Oct 19, 2022 13:01 HKT/SGT
Sirnaomics to Present Latest Developments on GalAhead(TM) Therapeutic Platform at Upcoming Industry Conferences
Sept 20, 2022 23:50 HKT/SGT
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
Sept 6, 2022 18:51 HKT/SGT
Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
Aug 29, 2022 12:46 HKT/SGT
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
Aug 26, 2022 20:15 HKT/SGT
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: